Search research articles
Contact Us
Filters
Showing results (41-50 of 92) with videos related to
Page
of 10
Sort By:
The American Journal of Clinical Nutrition
|
November 1, 1984
Excretion of urinary catecholamine metabolites in anorexia nervosa: effect of body composition and energy intake
J L Johnston, L A Leiter, G N Burrow, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
August 12, 2017
Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials
L A Leiter, D Müller-Wieland, M T Baccara-Dinet, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
June 18, 2011
Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study
L A Leiter, P Lundman, P M da Silva, et al.
The Journal of Clinical Endocrinology and Metabolism
|
July 1, 1984
L-thyroxine absorption in patients with short bowel
E Stone, L A Leiter, J R Lambert, et al.
Diabetes Care
|
July 1, 1995
Positive methane-producing status associated with increased serum cholesterol in subjects with impaired glucose tolerance
T M Wolever, J Fernandes, V A Rao, et al.
Atherosclerosis
|
April 29, 2006
Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study
P Martineau, A Gaw, E de Teresa, et al.
Diabetes & Metabolism
|
September 19, 2019
Alirocumab efficacy and safety by body mass index: A pooled analysis from 10 Phase 3 ODYSSEY trials
F J Tinahones, U Laufs, B Cariou, et al.
International Journal of Clinical Practice
|
October 16, 2010
Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin
L A Leiter, H Bays, S Conard, et al.
Diabetes Care
|
May 26, 2001
Diabetes Screening in Canada (DIASCAN) Study: prevalence of undiagnosed diabetes and glucose intolerance in family physician offices
L A Leiter, A Barr, A Bélanger, et al.
The American Journal of Physiology
|
September 1, 1982
Protein wasting due to acidosis of prolonged fasting
M C Hannaford, L A Leiter, R G Josse, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 92) with videos related to
Sort By:
Page
of 10
The American Journal of Clinical Nutrition
|
November 1, 1984
Excretion of urinary catecholamine metabolites in anorexia nervosa: effect of body composition and energy intake
J L Johnston, L A Leiter, G N Burrow, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
August 12, 2017
Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials
L A Leiter, D Müller-Wieland, M T Baccara-Dinet, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
June 18, 2011
Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study
L A Leiter, P Lundman, P M da Silva, et al.
The Journal of Clinical Endocrinology and Metabolism
|
July 1, 1984
L-thyroxine absorption in patients with short bowel
E Stone, L A Leiter, J R Lambert, et al.
Diabetes Care
|
July 1, 1995
Positive methane-producing status associated with increased serum cholesterol in subjects with impaired glucose tolerance
T M Wolever, J Fernandes, V A Rao, et al.
Atherosclerosis
|
April 29, 2006
Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study
P Martineau, A Gaw, E de Teresa, et al.
Diabetes & Metabolism
|
September 19, 2019
Alirocumab efficacy and safety by body mass index: A pooled analysis from 10 Phase 3 ODYSSEY trials
F J Tinahones, U Laufs, B Cariou, et al.
International Journal of Clinical Practice
|
October 16, 2010
Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin
L A Leiter, H Bays, S Conard, et al.
Diabetes Care
|
May 26, 2001
Diabetes Screening in Canada (DIASCAN) Study: prevalence of undiagnosed diabetes and glucose intolerance in family physician offices
L A Leiter, A Barr, A Bélanger, et al.
The American Journal of Physiology
|
September 1, 1982
Protein wasting due to acidosis of prolonged fasting
M C Hannaford, L A Leiter, R G Josse, et al.
Page
of 10